# Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

> **NCT04461119** · PHASE2 · COMPLETED · sponsor: **Newron Pharmaceuticals SPA** · enrollment: 138 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Evenamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04461119
- **Lead sponsor:** Newron Pharmaceuticals SPA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2021-02-20
- **Final completion:** 2021-03-13
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04461119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04461119, "Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04461119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*